Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Paroxysmal Supraventricular Tachycardia: full-pipeline trial registry
1 of 2 indexed Paroxysmal Supraventricular Tachycardia trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Paroxysmal Supraventricular Tachycardia: 2 US clinical trials tracked, 1 recruiting.
Paroxysmal Supraventricular Tachycardia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Milestone Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition paroxysmal-supraventricular-tachycardia
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Paroxysmal Supraventricular Tachycardia lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Paroxysmal Supraventricular Tachycardia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Paroxysmal Supraventricular Tachycardia is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Milestone Pharmaceuticals
NCT05763953
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Milestone Pharmaceuticals
NCT04072835
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Paroxysmal Supraventricular Tachycardia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Paroxysmal Supraventricular Tachycardia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Paroxysmal Supraventricular Tachycardia page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Paroxysmal Supraventricular Tachycardia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Milestone Pharmaceuticals sponsors the most Paroxysmal Supraventricular Tachycardia trials on record, review their full trial history before evaluating a specific study. See Milestone Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Paroxysmal Supraventricular Tachycardia condition card totals 2 registered trials; most-linked intervention Etripamil NS; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.